ERNA
Income statement / Annual
Last year (2023), Eterna Therapeutics Inc.'s total revenue was $68,000.00,
and the percentage change from the previous year is not available.
In 2023, Eterna Therapeutics Inc.'s net income was -$21.67 M.
See Eterna Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$68,000.00
|
$0.00
|
$0.00
|
$0.00
|
$19.81 M
|
$23.34 M
|
$21.27 M
|
$22.31 M
|
$24.52 M
|
| Cost of Revenue |
$236,000.00 |
$497,000.00 |
$459,000.00 |
$98,000.00 |
$7.84 M |
$8.39 M |
$7.09 M |
$8.13 M |
$13.06 M |
| Gross Profit |
-$168,000.00 |
-$497,000.00 |
-$459,000.00 |
-$98,000.00 |
$11.96 M |
$14.95 M |
$14.19 M |
$14.18 M |
$11.46 M |
| Gross Profit Ratio |
-2.47 |
0 |
0 |
0 |
0.6 |
0.64 |
0.67 |
0.64 |
0.47 |
| Research and Development
Expenses |
$5.92 M
|
$10.39 M
|
$12.71 M
|
$3.95 M
|
$26,000.00
|
$72,000.00
|
$139,000.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$14.59 M
|
$16.84 M
|
$14.72 M
|
$3.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$14.59 M
|
$16.84 M
|
$14.72 M
|
$3.30 M
|
$13.15 M
|
$14.41 M
|
$15.45 M
|
$16.46 M
|
$18.06 M
|
| Other Expenses |
$461,000.00 |
-$1.17 M |
$899,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$20.97 M |
$27.23 M |
$27.43 M |
$7.25 M |
$13.18 M |
$14.49 M |
$15.59 M |
$16.46 M |
$18.06 M |
| Cost And Expenses |
$21.20 M |
$27.23 M |
$27.43 M |
$7.25 M |
$21.02 M |
$22.87 M |
$22.68 M |
$24.59 M |
$31.12 M |
| Interest Income |
$138,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$3,000.00 |
| Interest Expense |
$614,000.00 |
$30,000.00 |
$74,000.00 |
$43,000.00 |
$249,000.00 |
$389,000.00 |
$498,000.00 |
$576,000.00 |
$484,000.00 |
| Depreciation &
Amortization |
$1.12 M
|
$497,000.00
|
$459,000.00
|
$98,000.00
|
$3.17 M
|
$2.76 M
|
$2.32 M
|
$2.89 M
|
$3.10 M
|
| EBITDA |
-$19.93 M
|
-$33.22 M
|
-$121.95 M
|
-$7.15 M
|
$1.96 M
|
$3.23 M
|
$915,000.00
|
$609,000.00
|
-$3.63 M
|
| EBITDA Ratio |
-293.15 |
0 |
0 |
0 |
0.1 |
0.14 |
0.04 |
0.03 |
-0.14 |
| Operating Income Ratio
|
-310.81
|
0
|
0
|
0
|
-0.06
|
0.02
|
-0.07
|
-0.1
|
-0.27
|
| Total Other
Income/Expenses Net |
-$536,000.00
|
$8.68 M
|
-$95.05 M
|
-$19.28 M
|
-$808,000.00
|
-$787,000.00
|
$391,001.00
|
-$607,000.00
|
-$614,000.00
|
| Income Before Tax |
-$21.67 M |
-$24.53 M |
-$122.30 M |
-$7.29 M |
-$2.02 M |
-$323,000.00 |
-$1.01 M |
-$2.89 M |
-$7.21 M |
| Income Before Tax Ratio
|
-318.69
|
0
|
0
|
0
|
-0.1
|
-0.01
|
-0.05
|
-0.13
|
-0.29
|
| Income Tax Expense |
-$3,000.00 |
$45,000.00 |
$5,000.00 |
-$19.20 M |
$27,000.00 |
-$64,000.00 |
$66,000.00 |
$38,000.00 |
$12,000.00 |
| Net Income |
-$21.67 M |
-$24.58 M |
-$122.31 M |
$11.91 M |
-$2.05 M |
-$259,000.00 |
-$1.08 M |
-$2.92 M |
-$7.23 M |
| Net Income Ratio |
-318.65 |
0 |
0 |
0 |
-0.1 |
-0.01 |
-0.05 |
-0.13 |
-0.29 |
| EPS |
-4.08 |
-8.06 |
-56.49 |
27.08 |
-28.48 |
-3.85 |
-17.64 |
-61.44 |
-157.26 |
| EPS Diluted |
-4.08 |
-8.06 |
-56.49 |
27.08 |
-28.48 |
-3.85 |
-17.64 |
-61.44 |
-157.26 |
| Weighted Average Shares
Out |
$5.31 M
|
$3.05 M
|
$2.17 M
|
$439,700.00
|
$71,875.00
|
$67,200.00
|
$61,050.00
|
$47,575.00
|
$45,949.00
|
| Weighted Average Shares
Out Diluted |
$5.31 M
|
$3.05 M
|
$2.17 M
|
$439,700.00
|
$71,875.00
|
$67,200.00
|
$61,050.00
|
$47,575.00
|
$45,949.00
|
| Link |
|
|
|
|
|
|
|
|
|
